Syros Pharmaceuticals Inc (LTS:0LC7)
$ 0.2 0 (0%) Market Cap: 5.44 Mil Enterprise Value: 7.39 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 18/100

Syros Pharmaceuticals Inc Conference Call Transcript

Dec 06, 2023 / 01:30PM GMT
Release Date Price: $3.9 (+39.26%)
Operator

Good morning and welcome to Syros Pharmaceuticals conference call. At this time, all participants are in a listen only mode. This call is being webcast live on the Investors and Media section at Cumulus website at www.cirrus.com. Please be advised that today's call is being recorded. At this time, I would like to turn the call over to Karen Hunady, Director of Investor Relations and Corporate Communications for key roles. Please go ahead.

Karen Hunady
Syros - Director of Corporate Communications & IR

Thank you. This morning we issued a press release announcing initial data from our Select and oh one Phase two clinical trial before release is available on the Investor & Media section of this Euroseas website at www.syros.com. We also have slides today that are viewable. If you're listening using the webcast and the slides can also be found on the Events section of the investor and media section of our website. We will begin the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot